How long do drugs stay in your system?

Why detection times vary so widely

Every published "detection window" for a drug is a range, not a number — and the spread of that range is usually wider than the people quoting it acknowledge. A donor's frequency of use, body composition, hepatic and renal function, hydration status, route of administration, and even the specific assay used all contribute. The same drug can be detectable in one donor for 24 hours and in another for ten days.

The variables that move detection times the most are frequency and dose. A single low-dose exposure clears quickly; cumulative chronic exposure builds up tissue stores (particularly for lipophilic compounds like THC) that release back into circulation over weeks. Half-life of the parent drug matters less than the half-life of the major urinary metabolite, because urine immunoassays are usually calibrated to the metabolite. And the assay's cutoff matters enormously — a 20 ng/mL screen will pick up far more long-tail use than a 50 ng/mL screen.

The other key variable is the specimen matrix. Urine reflects metabolite excretion over the prior hours-to-weeks. Saliva and blood reflect more recent exposure. Hair reflects use over the timeframe represented by the sample length — roughly one inch per month of growth. There is no single "correct" matrix; programs choose based on what they need to know.

Urine detection windows — the clinical reference

Urine is the dominant matrix for workplace, clinical, and forensic drug testing because metabolites concentrate there and remain detectable for days. The table below summarizes typical urinary detection windows at standard cutoffs.

Saliva, hair, and blood — when to use a different matrix

Urine is the default but not always the right choice. Saliva (oral fluid) has a shorter detection window and a better correlation with recent use and impairment, which matters for safety-sensitive workplace testing where the question is "are you currently impaired" rather than "did you use last weekend." SAMHSA has authorized oral fluid as a matrix for federal workplace testing, and adoption is growing.

Hair testing extends the detection window to roughly 90 days for a standard 1.5-inch sample, with the obvious limitation that it cannot tell you when within that window use occurred. Hair is often used in pre-employment screening, forensic investigations, and child-custody proceedings — settings where a longer lookback is valuable. It is less useful for acute concerns about current impairment or recent use.

Blood testing has the shortest detection window of any common matrix because parent drugs clear blood within hours. Blood is used in DUI investigations, post-mortem toxicology, and certain clinical and emergency-medicine settings, but it is impractical for routine workplace or clinical-monitoring programs. The major exception is post-accident testing, where blood is preferred precisely because it documents recent exposure.

Individual factors that move the window

Frequency of use is the single largest factor. Cumulative exposure builds up tissue stores — particularly for lipophilic substances like THC — that release back into circulation slowly over weeks. A donor who used once can clear within days; a chronic daily user can remain positive for weeks after stopping.

Body composition affects lipophilic-drug detection because adipose tissue serves as a reservoir. Higher body-fat percentage extends the detection window for THC and certain other lipid-soluble compounds. Rapid weight loss can transiently elevate urinary metabolites as fat stores are mobilized.

Hepatic and renal function determine how fast the body metabolizes and excretes most drugs. CYP-pathway induction (rifampin, carbamazepine, St. John's wort) generally shortens detection windows; CYP inhibition (ketoconazole, ritonavir, certain HIV antivirals) generally extends them. Renal impairment extends the detection of any drug whose metabolites are renally cleared — including norfentanyl, methadone metabolites, and most benzodiazepines.

Hydration affects the concentration of metabolites in a given urine sample. Heavy dilution lowers concentration and can push results below cutoff; federal programs use creatinine and specific-gravity testing to identify and reject dilute specimens. Dilution does not eliminate the metabolite — it lowers its concentration in that sample.

Route of administration changes pharmacokinetics. Inhaled and intravenous use produce rapid peaks; oral use produces slower onset and different metabolite ratios. Transdermal preparations (fentanyl patches, nicotine patches) produce relatively stable plasma concentrations over their dosing interval.

How to use detection times in program design

For random workplace testing, the standard windows above are sufficient. Urine immunoassays at SAMHSA cutoffs are calibrated to detect routine use without flagging incidental exposure. Programs concerned with recent-use evidence (post-accident, reasonable suspicion, return-to-duty) should consider oral fluid as a primary or supplemental matrix.

For substance-use treatment monitoring, programs commonly use shorter-window matrices (oral fluid, blood) for acute concerns and combine them with urine for sustained monitoring. The fentanyl epidemic has made fentanyl-specific testing essential in any treatment program; standard opiate immunoassays do not detect fentanyl, and a high proportion of patients in opioid-use-disorder treatment have fentanyl exposure history.

For DOT-regulated employees, follow 49 CFR Part 40 for matrix, cutoff, and procedure requirements. For federal civilian employees and federal-contractor programs, follow the SAMHSA Mandatory Guidelines. State-level workplace testing rules vary considerably and are increasingly restrictive in jurisdictions with legal cannabis programs.

For pre-employment screening, hair testing extends the lookback to roughly 90 days, which some employers value for safety-sensitive roles. Urine remains the dominant matrix for cost reasons. For pre-employment programs in states with cannabis-employment-protection laws, consult counsel before testing for THC.